Pipeline — registered trials by phase
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
— · Pulmonary Arterial Hypertension · Completed · est. 2019-09-19
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
— · Pulmonary Arterial Hypertension · Active Not Recruiting · est. 2026-04-30
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
— · Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease · Recruiting · est. 2030-09-01
TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
— · Pulmonary Arterial Hypertension · Completed · est. 2014-02-25
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
— · Pulmonary Arterial Hypertension · Completed · est. 2014-12
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
— · Pulmonary Arterial Hypertension · Completed · est. 2010-03
EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
— · Pulmonary Arterial Hypertension · Completed · est. 2022-05-11
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
— · Interstitial Lung Disease, Pulmonary Hypertension · Completed · est. 2026-03-13
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
— · Pulmonary Hypertension · Completed · est. 2008-01
Three Times Daily Dosing of UT-15C
— · Healthy · Completed · est. 2012-07
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
— · Pulmonary Arterial Hypertension · Completed · est. 2023-08-22
The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil
— · Pulmonary Arterial Hypertension, Renal Dysfunction · Completed · est. 2010-09
Effect of Food on the Pharmacokinetics of Oral Treprostinil
— · Hypertension, Pulmonary, Pulmonary Arterial Hypertension · Completed · est. 2009-11
A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers
— · Pulmonary Arterial Hypertension · Completed · est. 2010-08
A Study of CS231295 in Patients With Advanced Solid Tumors
— · Advance Solid Tumors, Advanced Malignant Solid Tumors · Not Yet Recruiting · est. 2027-12
Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers
— · Healthy · Completed · est. 2014-10
Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis
— · Systemic Sclerosis · Completed · est. 2010-01
Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities
— · Pulmonary Arterial Hypertension · Completed · est. 2010-08
Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine
— · Pulmonary Arterial Hypertension · Completed · est. 2010-08
Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
— · Pulmonary Arterial Hypertension · Completed · est. 2021-03-29
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine
— · Systemic Sclerosis, Scleroderma · Completed · est. 2011-03
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
— · Pulmonary Arterial Hypertension · Completed · est. 2017-06
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
— · Pulmonary Arterial Hypertension · Completed · est. 2013-11
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
— · ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation · Recruiting · est. 2029-11
5G-PEARL: Paxalisib in Malignant Brain Tumours
— · Malignant Primary Gliomas, Glioblastoma Multiforme (GBM) · Recruiting · est. 2029-01-19
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
— · PAH · Completed · est. 2017-07-20
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
— · ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation · Recruiting · est. 2028-10
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
— · Pulmonary Hypertension · Completed · est. 2013-01
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
— · Neuroblastoma · Completed · est. 2014-06
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
— · Pulmonary Hypertension · Completed · est. 2011-04
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
— · Progressive Pulmonary Fibrosis, Interstitial Lung Disease · Recruiting · est. 2027-11
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
— · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension · Completed · est. 2025-12-31
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
— · Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease · Completed · est. 2026-02-02
Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension
— · Pulmonary Hypertension · Completed
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
— · Pulmonary Hypertension · Completed · est. 2008-09
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
— · Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema · Completed · est. 2019-12-26
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
— · Pulmonary Arterial Hypertension · Completed · est. 2018-06-24
Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
— · Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease · Completed · est. 2025-06-30
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
— · Pulmonary Hypertension · Completed · est. 2007-10
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
— · Pulmonary Arterial Hypertension · Completed · est. 2021-08-12
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
— · Small Cell Lung Cancer · Completed · est. 2020-01-27
A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
— · Pulmonary Arterial Hypertension · Completed · est. 2013-11
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
— · Pulmonary Hypertension · Completed · est. 2011-07
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
— · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension · Enrolling By Invitation · est. 2026-12
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
— · Pulmonary Arterial Hypertension · Completed · est. 2020-02-12
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where United Therapeutics is lead sponsor; 45 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-08Current report (material event)
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- SCHEDULE 13G/A2026-08-13SCHEDULE 13G/A
- 8-K2026-08-05Current report (material event)
- 10-Q2026-08-05Quarterly report
- 8-K2026-07-23Current report (material event)
- S-8 POS2026-07-13S-8 POS
- S-8 POS2026-07-13S-8 POS
- S-8 POS2026-07-13S-8 POS
- S-8 POS2026-07-13S-8 POS
- S-8 POS2026-07-13S-8 POS
- S-8 POS2026-07-13S-8 POS
- S-8 POS2026-07-13S-8 POS
- S-8 POS2026-07-13S-8 POS
- S-8 POS2026-07-13S-8 POS
- S-82026-07-13Employee stock plan
- 8-K2026-06-29Current report (material event)
- SD2026-06-02SD
- 8-K2026-05-06Current report (material event)
- 10-Q2026-05-06Quarterly report
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- ARS2026-04-29Annual report to holders
- DEFA14A2026-04-29DEFA14A
- DEF 14A2026-04-29Proxy statement
- 8-K2026-03-30Current report (material event)
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 8-K2026-03-09Current report (material event)
- 8-K2026-03-02Current report (material event)
- 8-K2026-02-25Current report (material event)
- 10-K2026-02-25Annual report
- SCHEDULE 13G2026-02-10SCHEDULE 13G
- 8-K2026-01-22Current report (material event)
- 8-K2025-10-29Current report (material event)
- 10-Q2025-10-29Quarterly report
- 8-K2025-09-02Current report (material event)
- 8-K2025-08-01Current report (material event)
- S-82025-07-30Employee stock plan
- 8-K2025-07-30Current report (material event)
- 10-Q2025-07-30Quarterly report
- 8-K2025-06-27Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.